Carrie S. Cox - 12 Nov 2025 Form 4 Insider Report for Organon & Co. (OGN)

Reporting relationship: Executive Chair, Director
Issuer ticker: OGN
Reported as of: 12 Nov 2025
Net transaction value: +$501,755
SEC form: 4
Accepted by SEC: 13 Nov 2025, 16:05:10 UTC
Prior SEC filing: 16 Jun 2025
Next SEC filing: 02 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Carrie Smith Cox

Key filing fact

Carrie S. Cox filed Form 4 for Organon & Co. (OGN) on 13 Nov 2025.

Key facts

This page summarizes Carrie S. Cox's Form 4 filing for Organon & Co. (OGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Nov 2025, 16:05.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: +$501,755.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001110753 Primary reporting owner

COX CARRIE SMITH

Relationship: Executive Chair, Director
Address: C/O ORGANON & CO., 30 HUDSON STREET, FLOOR 33, JERSEY CITY
Signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Carrie Smith Cox
Signature date: 13 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OGN transaction

Common Stock

Purchase

Transaction value: $501,755
Shares: +65,400
Change %: +525%
Price: $7.67
Shares after: 77,869
Date: 12 Nov 2025
Ownership: IRA
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC remarks

Exhibit 24 - Power of Attorney